Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionCresset Asset Management, LLC
Latest Disclosed Ownership7,860 shares
Latest Disclosed Value $ 3,509,804
Cresset Asset Management, LLC ownership in VRTX / Vertex Pharmaceuticals Incorporated

On May 15, 2026 - Cresset Asset Management, LLC filed a 13F-HR form disclosing ownership of 7,860 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $3,509,804 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 7,555 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 4.04% during the quarter. The current value of the position is $3,512,084 USD.

Cresset Asset Management, LLC has a history of taking positions in derivatives of the underlying security (VRTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VRTX / Vertex Pharmaceuticals Incorporated Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,860 305 4.04 3,510 2.45 0.0152
2026-02-17 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,555 -37 -0.49 3,425 15.20 0.0144
2026-01-22 2025-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 7,592 -4,635 -37.91 2,973 -45.38 0.0130
2025-11-12 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,221 -3,006 3,611 0.0136
2026-01-22 2025-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 12,227 -2,100 -14.66 5,443 -21.64 0.0271
2025-08-13 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 14,143 -184 6,296 0.0273
2025-05-13 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 14,327 -1,691 -10.56 6,946 7.69 0.0346
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 16,018 -8,025 -33.38 6,450 -42.31 0.0308
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 24,043 8,004 49.90 11,182 48.74 0.0430
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 16,039 4,005 33.28 7,518 49.44 0.0316
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 12,034 961 8.68 5,030 11.65 0.0242
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 11,073 1,808 19.51 4,505 39.86 0.0269
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,265 -1,234 -11.75 3,222 -12.80 0.0124
2023-08-14 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 10,499 9,110 655.87 3,695 745.31 0.0046
2023-05-12 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,389 1,389 438 0.0088
2023-02-14 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -1,812 -100.00 0 -100.00
2022-11-14 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,812 -345 -15.99 524 -13.39 0.0066
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,157 -850 -28.27 605 -22.93 0.0074
2022-05-16 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 3,007 453 17.74 785 40.18 0.0082
2022-02-10 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,554 -465 -15.40 560 2.19 0.0054
2021-11-15 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 3,019 502 19.94 548 7.87 0.0074
2021-08-10 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,517 152 6.43 508 0.00 0.0072
2021-05-12 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 2,365 585 32.87 508 20.67 0.0080
2021-02-11 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,780 -317 -15.12 421 -26.14 0.0068
2020-11-13 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 2,097 165 8.54 570 1.60 0.0106
2020-08-04 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,932 542 38.99 561 69.49 0.0123
2020-05-15 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,390 253 22.25 331 32.93 0.0101
2020-02-10 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,137 1,137 249 0.0067
2019-11-13 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -1,212 -100.00 0 -100.00
2019-08-20 2019-06-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 1,212 104 9.39 222 8.82 0.0069
2019-08-12 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 1,212 104 222
2019-05-15 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,108 602 118.97 204 142.86 0.0079
2019-05-21 2018-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 506 506 84 0.0050
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM Call 100 47 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2025-05-13 2025-03-31 13F VERTEX PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2025-02-14 2024-12-31 13F VERTEX PHARMACEUTICALS COM Put 300 0.00 121 -13.67 n/a n/a n/a
2024-11-14 2024-09-30 13F VERTEX PHARMACEUTICALS COM Put 300 -85.71 140 -85.87 n/a n/a n/a
2024-08-14 2024-06-30 13F VERTEX PHARMACEUTICALS COM Put 2,100 -65.57 984 -61.40 n/a n/a n/a
2024-05-15 2024-03-31 13F VERTEX PHARMACEUTICALS COM Put 6,100 2,550 n/a n/a n/a
2024-02-14 2023-12-31 13F VERTEX PHARMACEUTICALS COM Put 0 -100.00 0 -100.00 n/a n/a n/a
2023-11-14 2023-09-30 13F VERTEX PHARMACEUTICALS COM Put 133,200 46,319 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.